Turnstone Biologics CorpNASDAQ:TSBX
- LAST PRICE2.6000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.5000/ 1
- Ask / Lots2.6000/ 2
- Open / Previous Close0.0000 / 2.6000
- Day Range---
- 52 Week Range
- Volume575
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TSBX |
|---|---|---|
| 09:32 ET | 347 | 2.6 |
| 09:34 ET | 108 | 2.715 |
| 09:57 ET | 100 | 2.625 |
| 10:01 ET | 100 | 2.66 |
| 10:03 ET | 500 | 2.66 |
| 10:06 ET | 200 | 2.66 |
| 10:08 ET | 300 | 2.66 |
| 10:10 ET | 100 | 2.66 |
| 10:12 ET | 498 | 2.66 |
| 10:24 ET | 100 | 2.66 |
| 10:26 ET | 600 | 2.63 |
| 10:35 ET | 1001 | 2.63 |
| 10:42 ET | 100 | 2.66 |
| 10:55 ET | 300 | 2.66 |
| 11:00 ET | 100 | 2.63 |
| 11:15 ET | 100 | 2.64 |
| 11:18 ET | 100 | 2.63 |
| 11:22 ET | 100 | 2.66 |
| 11:24 ET | 18395 | 2.56 |
| 11:26 ET | 163 | 2.56 |
| 11:29 ET | 1100 | 2.58 |
| 11:31 ET | 100 | 2.5684 |
| 11:33 ET | 180 | 2.58 |
| 11:36 ET | 410 | 2.58 |
| 11:40 ET | 200 | 2.5899 |
| 11:42 ET | 8155 | 2.55 |
| 11:44 ET | 2000 | 2.55 |
| 11:45 ET | 2883 | 2.5 |
| 11:47 ET | 300 | 2.53 |
| 11:49 ET | 4335 | 2.55 |
| 11:51 ET | 101 | 2.54 |
| 11:54 ET | 1800 | 2.56 |
| 11:58 ET | 3300 | 2.56 |
| 12:09 ET | 1000 | 2.55 |
| 12:16 ET | 1655 | 2.55 |
| 12:27 ET | 300 | 2.52 |
| 12:32 ET | 1010 | 2.533 |
| 12:34 ET | 144 | 2.56 |
| 12:36 ET | 2145 | 2.54 |
| 12:38 ET | 1000 | 2.55 |
| 12:39 ET | 100 | 2.54 |
| 12:41 ET | 1000 | 2.55 |
| 12:45 ET | 200 | 2.54 |
| 12:50 ET | 100 | 2.55 |
| 12:52 ET | 1505 | 2.54 |
| 12:57 ET | 100 | 2.55 |
| 12:59 ET | 100 | 2.535 |
| 01:03 ET | 100 | 2.53 |
| 01:08 ET | 100 | 2.53 |
| 01:15 ET | 1324 | 2.54 |
| 01:19 ET | 200 | 2.55 |
| 01:24 ET | 1000 | 2.535 |
| 01:28 ET | 1580 | 2.5203 |
| 01:33 ET | 414 | 2.55 |
| 01:35 ET | 1300 | 2.5499 |
| 01:37 ET | 100 | 2.5448 |
| 01:39 ET | 100 | 2.54 |
| 01:42 ET | 100 | 2.54 |
| 01:48 ET | 2700 | 2.56 |
| 01:50 ET | 300 | 2.55 |
| 01:53 ET | 100 | 2.54 |
| 02:08 ET | 250 | 2.55 |
| 02:09 ET | 100 | 2.56 |
| 02:15 ET | 300 | 2.54 |
| 02:18 ET | 5760 | 2.5 |
| 02:20 ET | 2583 | 2.4601 |
| 02:24 ET | 100 | 2.46 |
| 02:47 ET | 100 | 2.48 |
| 02:56 ET | 1961 | 2.47 |
| 02:58 ET | 277 | 2.48 |
| 03:05 ET | 300 | 2.4801 |
| 03:07 ET | 100 | 2.48 |
| 03:09 ET | 300 | 2.49 |
| 03:12 ET | 200 | 2.495 |
| 03:14 ET | 214 | 2.495 |
| 03:16 ET | 1801 | 2.495 |
| 03:18 ET | 300 | 2.5 |
| 03:20 ET | 300 | 2.49 |
| 03:21 ET | 1100 | 2.5 |
| 03:25 ET | 600 | 2.49 |
| 03:27 ET | 604 | 2.49 |
| 03:32 ET | 350 | 2.51 |
| 03:34 ET | 200 | 2.5 |
| 03:36 ET | 200 | 2.52 |
| 03:38 ET | 300 | 2.505 |
| 03:39 ET | 600 | 2.53 |
| 03:41 ET | 300 | 2.53 |
| 03:43 ET | 300 | 2.535 |
| 03:45 ET | 500 | 2.56 |
| 03:48 ET | 400 | 2.54 |
| 03:50 ET | 600 | 2.58 |
| 03:52 ET | 800 | 2.6 |
| 03:54 ET | 750 | 2.6 |
| 03:56 ET | 3483 | 2.6 |
| 03:57 ET | 2199 | 2.6 |
| 03:59 ET | 4378 | 2.6 |
Apr 16, 2024
Turnstone Biologics Appoints William Waddill to its Board of Directors, from 9:00AM ET on Tuesday Apr 16, 2024 by Dow Jones
9:00AM ET on Tuesday Apr 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Turnstone Biologics Corp | 60.1M | -1.0x | --- |
Celularity Inc | 66.0M | -0.3x | --- |
Prenetics Global Ltd | 61.6M | -1.1x | --- |
Aligos Therapeutics Inc | 59.8M | -0.4x | --- |
Cara Therapeutics Inc | 41.1M | -0.3x | --- |
ImmuCell Corp | 38.1M | -6.6x | --- |
Company Information
Turnstone Biologics Corp. is a clinical-stage biotechnology company. The Company is focused on developing new medicines to treat and cure patients with solid tumors. It is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. It is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. It is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.
Contact Information
- Headquarters
- 9310 Athena Circle, Suite 300LA JOLLA, CA, United States 92037
- Phone
- 347-897-5988
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Jerel Davis
- President, Chief Executive Officer, Director
- Sammy Farah
- Chief Financial Officer
- Venkat Ramanan
- Interim Chief Technology Officer
- Vijay Chiruvolu
- Chief Scientific Officer
- Stewart Abbot
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $60.1M |
|---|---|
Revenue (TTM) | $19.3M |
Shares Outstanding | 23.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.68 |
Book Value | $0.67 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | 3.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -305.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
